Acumen Pharmaceuticals Inc (ABOS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.58 (+0.39%), Market cap $0.17B, 52-week low–high $1.00 ~ $3.37.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquart
Financial statements, price targets, institutional (13F) holdings and related news for Acumen Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Acumen Pharmaceuticals Inc trades at $2.58 (+0.39%). Real-time quotes and charts are available on BlackAll Trade.
Acumen Pharmaceuticals Inc has a market cap of about $0.17B.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug ca